← Back to headlines
Travere Outlines 2026 Growth and FSGS Milestone
Travere Therapeutics has outlined its growth strategy driven by FILSPARI and a new milestone in FSGS research for 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
